Royal Bank Of Canada initiated coverage on shares of Galapagos NV (NASDAQ:GLPG) in a research report issued on Thursday, The Fly reports. The firm set a “sector perform” rating on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $92.00 target price on shares of Galapagos NV in a research report on Thursday, August 10th. Stifel Nicolaus raised shares of Galapagos NV from a “hold” rating to a “buy” rating and raised their target price for the company from $83.00 to $101.00 in a research report on Friday, August 11th. Cowen and Company reaffirmed a “buy” rating on shares of Galapagos NV in a research report on Thursday, August 10th. Janney Montgomery Scott raised shares of Galapagos NV from a “sell” rating to a “neutral” rating in a research report on Friday, July 7th. They noted that the move was a valuation call. Finally, BidaskClub raised shares of Galapagos NV from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $101.50.

Galapagos NV (NASDAQ GLPG) traded up 1.96% during midday trading on Thursday, hitting $103.46. 70,350 shares of the company traded hands. The stock’s 50-day moving average is $101.59 and its 200-day moving average is $84.97. Galapagos NV has a 12-month low of $57.16 and a 12-month high of $103.54.

TRADEMARK VIOLATION NOTICE: “Galapagos NV (GLPG) Coverage Initiated by Analysts at Royal Bank Of Canada” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/09/14/galapagos-nv-glpg-coverage-initiated-by-analysts-at-royal-bank-of-canada.html.

A number of hedge funds have recently made changes to their positions in the business. Cookson Peirce & Co. Inc. lifted its stake in Galapagos NV by 0.7% in the second quarter. Cookson Peirce & Co. Inc. now owns 3,045 shares of the biotechnology company’s stock valued at $233,000 after acquiring an additional 20 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in Galapagos NV in the second quarter valued at $214,000. Cubist Systematic Strategies LLC acquired a new stake in Galapagos NV in the second quarter valued at $704,000. EcoR1 Capital LLC lifted its stake in Galapagos NV by 5.0% in the second quarter. EcoR1 Capital LLC now owns 578,505 shares of the biotechnology company’s stock valued at $44,267,000 after acquiring an additional 27,464 shares during the last quarter. Finally, DAFNA Capital Management LLC lifted its stake in Galapagos NV by 9.2% in the second quarter. DAFNA Capital Management LLC now owns 38,609 shares of the biotechnology company’s stock valued at $2,954,000 after acquiring an additional 3,250 shares during the last quarter. Hedge funds and other institutional investors own 23.63% of the company’s stock.

About Galapagos NV

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

The Fly

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.